Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents

KAZUTAKA KOTO1,2, HIROAKI MURATA1, SHINYA KIMURA3, NAOYUKI HORIE1, TAKAAKI MATSU1, YASUNORI NISHIGAKI1, KAZUTERU RYU1, TOMOYA SAKABE1, MEGUMI ITOI1, EISHI ASHIHARA4, TAIRO MAEKAWA4, SHINJI FUSHIKI2 and TOSHIKAZU KUBO1

Departments of 1Orthopaedics, and 2Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566; 3Division of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501; 4Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyoku, Kyoto 606-8507, Japan

Received February 25, 2010; Accepted March 31, 2010

DOI: 10.3892/or_00000851

Abstract. Third-generation bisphosphonates are known to inhibit bone resorption and also appear to exhibit direct antitumour activity. We previously reported that third-generation bisphosphonates such as zoledronic acid (ZOL) have a direct antitumour effect, and synergistically augment the effects of antitumor agents in osteosarcoma cells. There has been no report on the antitumor effect of ZOL against soft tissue sarcoma. The aim of this study was to evaluate the antitumor effect of this drug on a human fibrosarcoma cell line, in terms of proliferation and apoptosis, and, moreover, to evaluate the combined effects of ZOL with other antitumor drugs against the human fibrosarcoma cell line. HT1080 cells were treated with ZOL at various concentrations up to 10 μM, and then cell proliferation, cell cycle, nuclear morphology, and Western blot analyses were performed to study the antitumor effects of ZOL alone, and, moreover, HT1080 cells were treated with ZOL and other anticancer drugs such as paclitaxel, docetaxel, doxorubicin, etoposide, 5-fluorouracil, gemcitabine, and cisplatin in human fibrosarcoma cells. We found that ZOL strongly inhibited in vitro proliferation, arrested the cell cycle between S and G2/M phases, and induced the apoptosis of human fibrosarcoma cells. Moreover, ZOL augmented the effect of antitumor agents when administered concurrently with paclitaxel, docetaxel, doxorubicin, etoposide, 5-fluorouracil, gemcitabine, and cisplatin in human fibrosarcoma cells. The combination of fibrosarcoma with ordinary antitumor drugs is not fully effective. These findings suggest that ZOL directly affects the proliferation and survival of fibrosarcoma cells, and that the combined administration of ZOL with other antitumor agents may improve the efficacy of fibrosarcoma treatment. These results support the possibility that their combined use could be beneficial in the treatment of patients not only with various types of cancer or osteosarcoma, but also with soft tissue sarcoma.

Introduction

Fibrosarcoma is one of the high-grade malignant soft tissue sarcomas that commonly occurs in middle-aged and older adults. Fibrosarcoma involves deep soft tissues of the extremities, trunk, head, and neck. Although the prognosis of these patients has improved due to the development of surgical treatment and various adjuvant chemotherapies, these therapies are not fully effective. The probability of local recurrence is related to the completeness of excision, with recurrence rates of 12-79% (1-3). Fibrosarcoma metastasizes to the lungs and bone, especially the axial skeleton. Metastasis occurs in 9-63% of patients, and is time- and grade-dependent. The 5-year survival rate of these patients is still 39-54% (2,3). For the improvement of treatment, novel antitumor drugs are urgently required.

Recently, many investigators have reported that bisphosphonates can directly inhibit the growth of various malignant cells, including multiple myeloma (4,5), leukemia (6), prostate cancer (7), and chondrosarcoma (8,9). Bisphosphonates are effective inhibitors of bone resorption and have been used for the last three decades in the treatment of
metabolic bone diseases (10). Nitrogen-containing bisphosphonates, or so-called second- and third-generation bisphosphonates, inhibit the activity of farnesyl diphosphate synthase (FPP synthase). This enzyme is required for the production of isoprenoid lipids necessary for the prenylation of small GTPases (11-13).

The inhibition of FPP synthase by nitrogen-containing bisphosphonates indirectly prevents protein prenylation, causing a loss of osteoclast function and apoptosis (14,15). Third-generation bisphosphonates, such as zoledronic acid (ZOL), are 10,000- to 100,000-fold more potent than the older-generation bisphosphonates (16). ZOL, the most potent nitrogen-containing bisphosphonate clinically available, has shown efficacy against bone cancer metastasis due to prostate cancer and other solid tumors, demonstrating that nitrogen-containing bisphosphonates can reduce skeletal morbidity in both osteolytic and osteoblastic diseases (35,36).

Recent pre-clinical in vitro and in vivo models have provided evidence that high doses of bisphosphonates may not only reduce bone loss through the inhibition of osteoclast activity, but may also exert direct antitumor and anti-angiogenic effects. Moreover, preclinical data have revealed that nitrogen-containing bisphosphonates can act on tumor cells by inhibiting tumor cell adhesion to mineralized bone as well as tumor cell invasion and proliferation (19-21).

We have also reported that bisphosphonates exhibit antitumor effects against osteosarcoma cells in in vitro and in vivo models (22,23), and that ZOL synergistically augments the effect of antitumor agents in osteosarcoma cell lines (23). Likewise, there are some reports concerning the combined effect of third-generation bisphosphonates with antitumor agents in various cancer cell lines (25-30).

For these reasons, bisphosphonates are assumed to be effective in inhibiting the growth of soft tissue sarcoma cells, by inhibiting the activity of FPP synthase. However, there has been no report on the antitumor effect of bisphosphonates against soft tissue sarcoma cells.

In this study, our purpose was to investigate the direct antitumor effect of ZOL against fibrosarcoma cells, which comprise one of the soft tissue sarcoma cell lines. To our knowledge, there has been no report on this tumor. Furthermore, we investigated the concurrent, combined effect of ZOL with other antitumor agents such as doxorubicin, etoposide, and paclitaxel.

Materials and methods

Reagents. ZOL (1-hydroxy-2-(1H-imidazole-1-yl) ethylidene-bisphosphonic acid) was obtained from Novartis Pharma AG (Basel, Switzerland). Doxorubicin (from Toronto Research Chemicals, Inc., Toronto, Canada), 5-fluorouracil (from Nacalai Tesque, Inc., Kyoto, Japan), cisplatin, paclitaxel, docetaxel, gemcitabine (from LKT laboratories, Inc., St. Paul, MN, USA), etoposide (from Calbiochem-Novabiochem, Cor(Merck KGaA), Darmstadt, Germany), and methotrexate (from Sigma Aldrich, Tokyo, Japan) were purchased from commercial sources. Appropriate drug concentrations were made by dilution with fresh medium immediately before each experiment.

Figure 1. Effects of ZOL on HT1080 cell growth. HT1080 cells were exposed to 0 (●), 0.5 (▲), 1.0 (■), 2.5 (◆), 5.0 (▲), or 10.0 (●) μM ZOL. Viable cells were counted by employing the trypan blue dye exclusion method. The data are presented as the means ± SD of at least three independent experiments.

Effects of ZOL on cell proliferation. Cell growth and viability were evaluated employing the trypan blue dye exclusion method. HT1080 cells were incubated in 6-well plates at a density of 2x10^4 in 2 ml of medium per well for 24 h, followed by the addition of 0, 0.5, 1.0, 2.5, 5.0, and 10.0 μM of ZOL. The viable cells in each well were counted at 0, 24, 48, and 72 h in vitro with a hemocytometer using the trypan blue dye exclusion method. The results are shown as means ± SD. The 50% growth inhibitory concentrations (IC_50) of ZOL were determined using the non-linear regression program CalcuSyn (Biosoft, Cambridge, UK).

Cell cycle analysis by flow cytometry. Untreated HT1080 cells or HT1080 cells treated with ZOL for 24, 48, and 72 h were analyzed for cell cycle alterations by staining with propidium iodide (Sigma Aldrich). The stained nuclei were analyzed using a FACSCalibur flow cytometer (Becton-Dickinson, Tokyo, Japan). DNA histograms were created using Cell Quest software for Apple Macintosh (Becton-Dickinson).

Analysis of nuclear morphology. Untreated HT1080 cells and HT1080 cells treated with 2.5 μM ZOL were cultured for 48 h, fixed with 2% paraformaldehyde in PBS for 10 sec, and then stained with DAPI (4,6-diamidino-2-phenylindole dihydrochloride) (Nacalai Tesque) at 4°C in the dark. For fluorescence microscopy, cells were cytospun onto slides and examined using a universal microscope (Nikon, Tokyo, Japan) with UV illumination. Apoptotic cells were defined on the basis of characteristic changes including nuclear condensation, fragmentation, and apoptotic bodies.
Western blot analysis. To extract HT1080 proteins, the cells were seeded in culture dishes with various concentrations of ZOL for 24-72 h. Protein samples were extracted from 3x10^6 cells, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and blotted onto a nitrocellulose membrane (Amersham Biosciences, Tokyo, Japan). The membranes were saturated with 5% (wt/vol) non-fat dry milk in TBST [25 mM Tris HCl (pH 7.8), 140 mM NaCl, 0.1% (vol/vol) Tween-20], and then incubated overnight with goat polyclonal anti-Rap1A antibody (diluted 1:1,000) (Santa Cruz Biotechnologies, CA, USA). Rap 1A is a substrate of geranylgeranyl transferase (GGTase I) (33). The membranes were washed thoroughly with TBST and incubated for 1 h with anti-goat IgG coupled with horseradish peroxidase (Santa Cruz Biotechnologies). Detection was performed with enhanced chemiluminescence kits (Amersham Biosciences).

Concurrent exposure to ZOL and other antitumor agents. To investigate the combined effect of ZOL with other antitumor agents, HT1080 cells were treated with 1.2 μM, which is about the IC_{50}, of ZOL alone, antitumor drugs such as doxorubicin, cisplatin, etoposide, 5-fluorouracil, docetaxel, paclitaxel, gemcitabine, and methotrexate alone, and ZOL/antitumor drug combinations in 6-well plates for 72 h. The IC_{50} after 72 h of each antitumor drug was decided employing the trypan blue dye exclusion method and calculated using the non-linear regression program CalcuSyn mentioned above. Proliferation of the cell lines was determined using the trypan blue dye exclusion method, as described above. HT1080 cells were incubated in 6-well plates at a density of 2x10^4 in 2 ml of medium per well for 24 h, followed by an additional 1.2 μM of ZOL alone, other antitumor agents alone, and the ZOL/antitumor drug combination in 6-well plates for 72 h. The viable cells in each well were counted at 72 h in vitro. The means of three data values for each treatment were calculated. The results are shown as means ± SD. These cell cycles were also analyzed using the flow cytometry method described above. P-values <0.05 were considered significant, and were derived from two-sided statistical tests.

Results

Growth inhibition of fibrosarcoma cell lines by ZOL. ZOL inhibited the growth of HT1080 cells, as shown in Fig. 1. HT1080 cell growth was inhibited by ZOL in a time- and dose-dependent manner. The IC_{50} of ZOL after 48 and 72 h of exposure was 1.66 and 1.26 μM, respectively. Thus, ZOL effectively inhibited fibrosarcoma cell growth. Furthermore, a high concentration of ZOL over 2.5 μM demonstrated a cytotoxic effect.
Effect of ZOL on the cell cycle and induction of apoptosis in HT1080 cells. Cell cycle analysis were performed on HT1080 cells after 24, 48, or 72 h of concurrent exposure to ZOL to observe events on a DNA histogram. These results revealed an increase of cells in the S phase between the G0/G1 and G2/M phases in a dose-dependent manner after 24- or 48-h concurrent exposure to ZOL (Fig. 2A and B). The proportion of cells in sub-G1 increased in a time- and dose-dependent manner, especially when they were exposed to a high concentration (over 2.5 μM) of ZOL (Fig. 2C). A low concentration of ZOL altered the cell cycle, and a high concentration induced an increase in Sub-G1 in human fibrosarcoma cells.

Effect of ZOL on nuclear morphology. HT1080 cells treated for 48 h with 2.5 μM ZOL and stained with DAPI showed nuclear fragmentation and apoptotic bodies that are characteristic of apoptosis (Fig. 3).

Effect of ZOL on small GTP-binding protein prenylation and the induction of apoptosis in HT1080 cells. HT1080 cells treated for 24 and 48 h with 2.5, 5.0, and 10.0 μM ZOL were lysed and analyzed by Western blotting using an antibody that specifically recognizes the unprenylated form of Rap1A and cleaved caspase-3, and an antibody for tubulin. The data shown are representative of three independent experiments.

Table I. IC_{50} values of antitumor drugs for 72 h.

<table>
<thead>
<tr>
<th>Drug</th>
<th>IC_{50} (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>4.7</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>947.5</td>
</tr>
<tr>
<td>Etoposide</td>
<td>135.0</td>
</tr>
<tr>
<td>5-fluorouracil</td>
<td>178.2</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>6.9</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>1.7</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>87.7</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>8.7</td>
</tr>
</tbody>
</table>

Concurrent combined effects of ZOL with other antitumor agents. Cytotoxic interactions on the concurrent exposure of cells to ZOL and other antitumor drugs. The IC_{50} at 72 h of each antitumor drug is shown in Table I. When combined with a concentration of 0.5xIC_{50} and 1.0xIC_{50} values for doxorubicin, cisplatin, etoposide, 5-fluorouracil, docetaxel, paclitaxel, and gemcitabine, the growth inhibitory effects were much more markedly augmented compared to ZOL alone or antitumor drugs alone. When we used ZOL together with docetaxel or etoposide, the P-value was <0.001, and the combination effect was particularly marked. In contrast, when combined with methotrexate, The P-value exceeded 0.05, indicating that combination with methotrexate has antagonistic rather than additive or synergistic effects. Only MTX did not show a combined effect (Fig. 5).

Effects of ZOL and other antitumor drugs on the cell cycle and induction of cell death. As described above, significant inhibitory effects of etoposide or docetaxel with ZOL were noted in HT1080 cells. To investigate the possible mechanisms, we analyzed the effects of these anticancer agents on the cell cycle. When HT1080 cells were treated with 1.2 μM ZOL combined with 70 nM (approximately equal to 0.5xIC_{50}) or 140 nM (approximately equal to 1.0xIC_{50}) etoposide for 72 h, there was an increase in the proportion of HT1080 cells only in sub-G1. In the histogram, the G1-, S-, and G2/M-phases were not so markedly changed by combined treatment compared to each drug alone. These results are similar to those for HT1080 cells treated with docetaxel, doxorubicin, cisplatin, 5-fluorouracil, paclitaxel, and gemcitabine for 72 h. These suggest that when ZOL is combined with etoposide or other anticancer agents except for methotrexate, ZOL might augment the cytotoxic effect of anticancer agents (Fig. 6, Table II).

Discussion

We have demonstrated that the third-generation bisphosphonate, ZOL, inhibits the proliferation of fibrosarcoma cell lines. As far as we know, there have been no reports on the antitumor effect of bisphosphonates on soft tissue treatment. Cleaved caspase-3 was not detected in untreated HT1080 cells after 24 h of ZOL treatment, but was detected after 48-h treatment (Fig. 4).
Figure 5. Growth inhibitory effects of concurrent treatment with ZOL and anticancer agents on human fibrosarcoma cell lines. The capacity of ZOL and several antitumor agents to inhibit the growth of HT1080 cells was determined by employing the trypan blue dye exclusion method. Data from three independent experiments were collected, and Student's t-test was used to evaluate the efficacy of concurrent treatment with ZOL and other agents and to compare the effects of each anticancer agent alone. P-values of <0.05 were considered statistically significant and derived from two-sided statistical tests. X-axis: a, control; b, 1.2 μM of ZOL alone; c, 0.5xIC50 of antitumor drug alone; d, combination of b with c; e, 1.0xIC50 of antitumor drug; f, combination of b with d. Y-axis is cell counts (x10^5). (A) doxorubicin; (B) cisplatin; (C) etoposide; (D) 5-fluorouracil; (E) docetaxel; (F) paclitaxel; (G) gemcitabine; (H) methotrexate.

Table II. Sub-G1 (%) in the cell cycle of HT1080 cells is shown.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5xIC50</td>
<td>5.51</td>
<td>6.00</td>
<td>7.48</td>
<td>1.83</td>
<td>9.66</td>
<td>2.85</td>
<td>2.89</td>
<td>1.65</td>
</tr>
<tr>
<td>ZOL 1.2 μM + 0.5xIC50</td>
<td>29.23</td>
<td>14.99</td>
<td>32.15</td>
<td>11.4</td>
<td>43.98</td>
<td>11.43</td>
<td>12.34</td>
<td>4.84</td>
</tr>
<tr>
<td>1.0xIC50</td>
<td>7.33</td>
<td>21.09</td>
<td>8.69</td>
<td>2.33</td>
<td>26.64</td>
<td>6.85</td>
<td>3.18</td>
<td>2.96</td>
</tr>
<tr>
<td>ZOL 1.2 μM + 1.0xIC50</td>
<td>32.75</td>
<td>21.63</td>
<td>39.89</td>
<td>15.06</td>
<td>50.09</td>
<td>24.04</td>
<td>24.31</td>
<td>4.39</td>
</tr>
</tbody>
</table>

HT1080 cells were treated with 0.5xIC50 and 1.0xIC50 of each agent, and 1.5 μM ZOL with 0.5xIC50 and 1.0xIC50 of each agent. In both the treatment of 1.2 μM ZOL with 0.5xIC50 anticancer agent and 1.2 μM ZOL with 1.0xIC50 antitumor agent, the proportion of cells in the sub-G1 increased by >20% by the combination of ZOL and doxorubicin, etoposide, and docetaxel. The data shown are representative of three independent experiments. A, doxorubicin; B, cisplatin; C, etoposide; D, 5-fluorouracil; E, docetaxel; F, paclitaxel; G, gemcitabine; H, methotrexate.

Figure 6. Cell cycle analysis of combined treatment of ZOL with etoposide. The effect of agents on the cell cycle was evaluated by flow cytometry of fibrosarcoma cells that had been exposed to different agent concentrations for 72 h. HT1080 cells, untreated (i); 70 nM (approximately equal to 0.5xIC50) etoposide (ii); 140 nM (approximately equal to 1.0xIC50) etoposide (iii); 1.2 μM ZOL (iv); 1.2 μM ZOL with 70 nM etoposide (v); and 1.2 μM ZOL with 140 nM etoposide (vi). Data on other antitumor agents alone, and the combination treatment of other antitumor agents with ZOL are not shown.
sarcoma, and this is the first report. Nitrogen-containing bisphosphonates are known to block the mevalonate pathway by inhibiting the activation of small GTP-binding protein prenylation (11-13).

We have also shown that ZOL, one of the third-generation bisphosphonates, blocked the prenylation of Rap1A proteins and induced cleaved caspase-3 in a dose- and time-dependent manner in the fibrosarcoma cell line. Since the Ras/MAPK pathway is crucial for regulating intracellular signaling in the proliferation of tumor cells (34-36), blockage of the prenylation of small GTP-binding protein could result in blockage of the mevalonate pathway, which inhibits tumor growth. Recent studies have also shown that bisphosphonates can directly affect the proliferation and survival of a variety of tumor cells, including multiple myeloma, leukemia, prostate cancer, and osteosarcoma (4-7).

However, the precise mechanism is not yet sufficiently understood. In order to gain further insight into the mechanism of action, we have analyzed cell cycle changes using flow cytometry: ZOL facilitated apoptosis between the S phase and G2/M boundary. Furthermore, ZOL induced apoptotic bodies in fibrosarcoma cells when stained with DAPI. These results, cell cycle arrest and apoptosis induction, indicated that ZOL might cause DNA damage. However, as we have previously reported in osteosarcoma cells, it is difficult to clarify the mechanism only through alteration of the cell cycle.

The present study showed that the IC50 values of ZOL for fibrosarcoma cell lines ranged from 1 to 2 μM, although reports on leukemia, multiple myeloma, and osteosarcoma cells reported that the IC50 values of third-generation BPs ranged from 1 to 100 mM (4-6). Following an infusion of the standard dose of zoledronic acid (4 mg), peak plasma levels were only 1-2 μM (26). Therefore, considering the IC50, third-generation BPs could be very useful to treat patients with fibrosarcoma. However, ZOL is rapidly cleared from the circulation within 1-2 h (7). It is therefore likely that peripheral tumors are exposed to a low concentration of ZOL for only a few hours, and that the effects of ZOL alone might be insufficient in vivo.

Therefore, to increase the antitumor effects, we subsequently investigated the potential antitumor effects of ZOL combined with the commonly used chemotherapeutic agents. ZOL augmented the cytotoxic effect and showed the synergistic induction of apoptosis in vitro when combined with paclitaxel, etoposide, cisplatin, and irinotecan in lung cancer cells (20), with gemcitabine in colon cancer cells (21), with doxorubicin, paclitaxel, and tamoxifen in breast cancer cells (25,28), with dexamethasone in myeloma cells (39), and with paclitaxel, cisplatin, gemcitabine, and doxorubicin in murine osteosarcoma cells (24). In the present study, combined treatment of ZOL with paclitaxel, docetaxel, etoposide, cisplatin, gemcitabine, doxorubicin, or 5-fluorouracil showed a marked cytotoxic effect against human fibrosarcoma cells compared to the single use of these agents. Above all, the combined effect of etoposide, doxorubicin, and docetaxel tended to be marked regarding not only inhibition, but also the sub-G1 effect. These results suggest that combined treatment of ZOL with commonly used agents for soft tissue sarcoma also has the possibility of reducing the side effects of the antitumor agents. In the case of antitumor agents used for elderly patients, even if they are administered at a lower dose, equal effects may be expected when treated combined with ZOL.

There are some reports on the mechanism of the synergistic interaction between ZOL and chemotherapeutic agents. The synergistic induction of apoptosis in breast cancer cells achieved by the combination of ZOL and paclitaxel or doxorubicin is sequence-dependent, with synergistic levels of apoptosis only being achieved when breast cancer cells are pre-treated with doxorubicin or paclitaxel followed by ZOL (20,25,28,30). We showed that ZOL did not alter the cell cycle, but only increased the proportion of sub-G1 fibrosarcoma cells in the case of concurrent exposure. These results are thought to show that ZOL enhanced only the cytotoxic activity of anticancer agents, and did not influence the cell cycle. However, in human fibrosarcoma cells, like breast cancer cells, differences may be reflected in the antitumor effect based on the dosage method.

In contrast, ZOL combined with MTX administered to HT1080 cell lines showed antagonistic effects. This antagonistic effect of MTX was also seen in leukemic and murine osteosarcoma cells (40). It has been noted that one agent might reduce the cytotoxicity of the other agent by preventing cells from entering the specific phase in which they are most sensitive to the other agent. Although the reason for this antagonism has not been fully clarified, the simultaneous administration of ZOL with MTX might be counterproductive not only in the treatment of fibrosarcoma, but also in other cancers. Therefore, the clinical use of ZOL should be evaluated carefully to avoid adverse interactions.

When we consider that ZOL is rapidly cleared from the circulation, and even concurrent exposure exhibits a marked antitumor effect in vitro, sequential treatment involving the administration of other antitumor agents followed by ZOL might be clinically recommended, even though further studies on the dosage should be conducted.

These results suggest that ZOL could be beneficial in the treatment of fibrosarcoma patients. Furthermore, the combined administration of ZOL with other antitumor agents may be effective compared to the use of any of these agents or ZOL alone. Treatment using ZOL may improve the prognosis of patients with fibrosarcoma.

Acknowledgements

This work was supported by KAKENHI (Grant-in-Aid for Scientific Research C: 20591764 to H.M.).

References


